Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Navigating Manager Selection Risk in Private Credit

BY | ETF Database
7:17 am ET 05/08/26 | 10 VIEWS
  • Related Symbols
  • PCR
Private credit has emerged as an attractive asset class for investors seeking enhanced returns, but recent data reveals a critical challenge: manager selection risk. Notably, the 54 constituents in the VettaFi Private Credit Index showed dramatic performance dispersion in 2025. Returns ranged from positive 20% to negative 30% – a staggering 50-percentage-point spread.Key Takeaways Performance dispersion in private credit reached 50 percentage points in 2025, highlighting the extreme risks associated with individual manager selection. Traditional private credit investing requires a difficult two-step process: deciding on the asset allocation and then vetting specific managers. The Simplify Private Credit Strategy ETF (PCR) offers an index-based solution that mitigates selection risk by providing broad, diversified exposure to the asset class. The Manager Selection Dilemma This wide dispersion creates a significant dilemma for investors. “If you were invested in the manager who was up 20%, you’re probably quite pleased with your exposure. On the other hand, if you were invested in the manager who had a 30% negative return, you’re probably not so happy,” Christopher Getter, portfolio manager at Simplify Asset Management, said during a recent webcast. Traditionally, private credit investing requires a two-step process. First, making an asset allocation decision to invest in private credit. Second, selecting which manager to invest with. This manager selection decision carries substantial risk, as the 2025 data clearly demonstrates. For advisors, the stakes are particularly high. The consequences of poor manager selection can significantly impact client relationships and portfolio performance.An Index-Based Solution to Private Credit RiskThe Simplify Private Credit Strategy ETF (PCR) addresses this challenge by taking a different approach. Rather than requiring investors to navigate the manager selection minefield, PCR "invests in the entire index, so you will get a much more diversified exposure over the very large breadth of issuers that are active in the private credit space,” Getter said. This approach consolidates the traditional two-step process into a single decision. “If you just want that to be one decision, which is the asset allocation decision into private credit, PCR is a very expedient way to get that,” Getter explained. By providing broad index exposure, PCR mitigates manager selection risk while maintaining access to the private credit asset class. For more news, information, and strategy, visit ETFDB. vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for PCR, for which it receives an index licensing fee. However, PCR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of PCR.

More Commentary

State Streets Doshi on Gold's Portfolio Use Cases & More
BY | ETF Database
5:02 am ET 05/08/26 | 18 VIEWS
AMD Ascent Could Lure Traders to This ETF
BY | ETF Database
8:58 am ET 05/08/26 | 17 VIEWS
Meet WDIG: WisdomTrees New Rare Earth & Metals ETF
BY | ETF Database
05/07/2026 | 36 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.